Merck Reports Phase 3 extension Data for Upadacitinib in Sjögren's syndrome

Merck today announced Phase 3 extension results for Upadacitinib in patients with Sjögren's syndrome. The study demonstrated that Upadacitinib improves quality of life measures compared to standard of care or placebo. These results provide important insights into the treatment of Sjögren's syndrome and support the continued development of Upadacitinib in this patient population. The data were presented at a major medical conference and will be submitted for publication in a peer-reviewed journal. Regulatory submissions are planned based on these results. The safety profile of Upadacitinib was consistent with previous observations, with no new safety signals identified.